TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancersTushar D. Nichakawade, Suman Paul, Sandra B. Gabelli et al.|Nature|2024Cited by 43
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densitiesBrian J. Mog, Shibin Zhou, Nikita Marcou et al.|Science Translational Medicine|2024Cited by 23
Abstract LB095: Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigenBrian J. Mog, Shibin Zhou, Sarah R. DiNapoli et al.|Cancer Research|2023Cited by 1
TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancersJiaxin Ge, Joshua Urban, Sarah R. DiNapoli et al.|Nature Cancer|2025Cited by 1
Bispecific antibodies and CAR T cells targeting a TP53 mutation–associated neoantigen show discordant affinity requirementsSarah R. DiNapoli, Bert Vogelstein, Katharine M. Wright et al.|Journal of Clinical Investigation|2026Cited by 0